PRESS RELEASE
13 May 2025

Lowenstein Represents Inductive Bio In $25M Series A Financing To Transform Small Molecule Drug Discovery With Industry-Wide AI Platform

LS
Lowenstein Sandler

Contributor

Lowenstein Sandler is a national law firm with over 350 lawyers working from five offices in New York, Palo Alto, New Jersey, Utah, and Washington, D.C. We represent clients in virtually every sector of the global economy, with particular strength in the areas of technology, life sciences, and investment funds.
Lowenstein Sandler represented Inductive Bio in $25 million Series A financing to transform small molecule drug discovery with an industry-wide AI platform.
United States

Lowenstein Sandler represented Inductive Bio in $25 million Series A financing to transform small molecule drug discovery with an industry-wide AI platform. Obvious Ventures led the funding round with participation from Andreessen Horowitz (a16z) Bio + Health, Lux Capital, S32, Character, and Amino Collective, as well as participation from angel investors Oren Etzioni, Jeff Hammerbacher, Malay Gandhi, and Jakob Uszkoreit.

Inductive intends to use the funding to expand its AI model R&D, grow its pre-competitive data consortium, and deploy its technology industry-wide, thus leveling the playing field for both innovative startups and large pharmaceutical companies. In the long term, the company plans to launch an AI-native contract research organization on top of its technology.

The Lowenstein team included Eric Weiner, Frank W. Eucalitto, Jun Hyon "Henry" Nahm, and Sophia Yi-Hun Kim.

Contributor

Lowenstein Sandler is a national law firm with over 350 lawyers working from five offices in New York, Palo Alto, New Jersey, Utah, and Washington, D.C. We represent clients in virtually every sector of the global economy, with particular strength in the areas of technology, life sciences, and investment funds.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More